The collagen-like component of the complement system, C1q, is recognized by 7 S autoantibodies and is functionally impaired in synovial fluids of patients with rheumatoid arthritis.

PubWeight™: 0.79‹?›

🔗 View Article (PMC 1384102)

Published in Immunology on March 01, 1996

Authors

P K Trinder1, M J Maeurer, D Brackertz, M Loos

Author Affiliations

1: Institute of Medical Microbiology and Hygiene, Johannes Gutenberg University, Mainz, Germany.

Articles cited by this

Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05

Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med (1977) 10.09

Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q. Clin Exp Immunol (1976) 4.97

Isolation, by partial pepsin digestion, of the three collagen-like regions present in subcomponent Clq of the first component of human complement. Biochem J (1976) 2.62

Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum (1989) 1.95

Consideration of pathogenesis of rheumatoid arthritis as collagen autoimmunity. Z Immunitatsforsch Allerg Klin Immunol (1970) 1.67

Collagen-induced arthritis in mice. Localization of an arthritogenic determinant to a fragment of the type II collagen molecule. J Exp Med (1985) 1.52

Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med (1989) 1.39

Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum (1985) 1.33

Oxygen radicals as effectors of cartilage destruction. Direct degradative effect on matrix components and indirect action via activation of latent collagenase from polymorphonuclear leukocytes. Arthritis Rheum (1986) 1.28

Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum (1988) 1.20

IgG and IgA antibodies to the collagen-like region of C1q in rheumatoid vasculitis. Arthritis Rheum (1990) 1.04

Characterization of a tolerogenic T cell epitope of type II collagen and its relevance to collagen-induced arthritis. J Immunol (1992) 1.02

Low molecular weight C1q in systemic lupus erythematosus. J Immunol (1985) 1.00

Assessment of the potential pathogenicity of type II collagen autoantibodies in patients with rheumatoid arthritis. Evidence of restricted IgG3 subclass expression and activation of complement C5 to C5a. Arthritis Rheum (1986) 0.93

The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes. Prog Allergy (1982) 0.89

60-kDa Ro protein autoepitopes identified using recombinant polypeptides. J Immunol (1994) 0.85

C1q-bearing immune complexes detected by a monoclonal antibody to human C1q in rheumatoid arthritis sera and synovial fluids. Rheumatol Int (1991) 0.82

The reconstitution of human C1, the first complement component: binding of C1r and C1s to C1q influences the C1q conformation. FEBS Lett (1981) 0.82

Enzymatic alteration of C1q, the collagen-like subcomponent of the first component of complement, leads to cross-reactivity with type II collagen. FEBS Lett (1988) 0.81

Detection of C1q-bearing immune complexes by a monoclonal anti-C1q ELISA system. J Immunol Methods (1987) 0.80

Common epitopes in Clq and collagen type II. Mol Immunol (1989) 0.80

Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q. J Immunol (1984) 0.79

Enzyme-linked immunosorbent assay for C1q in human serum by use of monoclonal antibodies. J Immunol Methods (1984) 0.79

Guinea pig macrophages synthesize a low molecular weight form of C1q with affinity for the C1r2C1s2-complex but which does not bind to Fc in immunoglobulin aggregates. Mol Immunol (1988) 0.78

Improved standardization in the quantitative estimation of soluble immune complexes making use of an international reference preparation. Results of a collaborative multicentre study. Clin Exp Immunol (1984) 0.78

Arthritis-regulating determinants on the collagen-like complement component C1q. Immunol Today (1992) 0.78

C1q in autoimmune diseases: rheumatoid arthritis. Behring Inst Mitt (1993) 0.77

Modulation of type II collagen-induced arthritis in DBA/1 mice by intravenous application of a peptide from the C1q-A chain. Immunobiology (1992) 0.77

Articles by these authors

Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20

Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum (1977) 3.23

HL-A antigens in sarcoidosis and rheumatoid arthritis. Lancet (1972) 1.84

Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82

Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol (1978) 1.79

Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78

Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 1.75

Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol (1974) 1.69

Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol (1993) 1.69

Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64

Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun (1978) 1.60

Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43

TAP off--tumors on. Immunol Today (1997) 1.43

A 66-kilodalton heat shock protein of Salmonella typhimurium is responsible for binding of the bacterium to intestinal mucus. Infect Immun (1992) 1.41

Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem (1996) 1.35

Toxoplasma gondii down-regulates MHC class II gene expression and antigen presentation by murine macrophages via interference with nuclear translocation of STAT1alpha. Eur J Immunol (2001) 1.30

Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol (2000) 1.25

Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med (1995) 1.24

Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23

[Measurement of complement with a microliter method]. Z Med Mikrobiol Immunol (1969) 1.22

Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum (1988) 1.20

Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry (1976) 1.20

Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry (1976) 1.20

Studies on antigen-induced arthritis in mice. III. Cell and serum transfer experiments. J Immunol (1977) 1.18

Interactions between mycoplasma pneumoniae and the first components of complement. Infect Immun (1977) 1.17

HL-A antigens of patients with sarcoidosis. Tissue Antigens (1974) 1.15

Identification of a unique Helicobacter species by 16S rRNA gene analysis in an abdominal abscess from a patient with X-linked hypogammaglobulinemia. J Clin Microbiol (2000) 1.15

Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells. J Immunol (2001) 1.14

Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med (1987) 1.14

Inflammation in areas of remote changes following focal brain lesion. Prog Neurobiol (2005) 1.11

Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol (2000) 1.11

PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer (2010) 1.11

vacA genotypes and genetic diversity in clinical isolates of Helicobacter pylori. Clin Diagn Lab Immunol (1998) 1.10

Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy? J Clin Microbiol (1999) 1.07

Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry (1976) 1.07

Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera. Immunology (1980) 1.05

Follicular dendritic cells, interdigitating cells, and cells of the monocyte-macrophage lineage are the C1q-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J Immunol (1995) 1.04

Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03

Antibody-independent killing of gram-negative bacteria via the classical pathway of complement. Immunol Lett (1987) 1.03

Studies on antigen-induced arthritis in mice. II. Immunologic correlates of arthritis susceptibility in mice. J Immunol (1977) 1.03

Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis. Genes Immun (2007) 1.02

Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol (2001) 1.01

Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis. J Neurol Sci (1995) 0.99

Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens: combination of TCR-CDR3 spectratyping with flow cytometry-based TCR VB frequency analysis. Clin Diagn Lab Immunol (2002) 0.98

Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int (1988) 0.97

Evidence for direct binding of the first component of complement, C1, to outer membrane proteins from Salmonella minnesota. Curr Top Microbiol Immunol (1985) 0.97

In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015). Eur J Cancer Clin Oncol (1987) 0.97

Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages. Curr Top Microbiol Immunol (1983) 0.95

Interaction of purified lipoteichoic acid with the classical complement pathway. Infect Immun (1986) 0.94

The role of accessory cells in polyclonal T cell activation. I. Both induction of interleukin 2 production and of interleukin 2 responsiveness by concanavalin A are accessory cell dependent. Eur J Immunol (1983) 0.94

Proteinase inhibitors in rheumatoid arthritis. Ann Rheum Dis (1975) 0.94

Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother (1998) 0.94

Requirement for an additional serum factor essential for the antibody-independent activation of the classical complement sequence by Gram-negative bacteria. Infect Immun (1982) 0.93

High-throughput phenotyping of avoidance learning in mice discriminates different genotypes and identifies a novel gene. Genes Brain Behav (2012) 0.93

Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav (2006) 0.92

Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol (1982) 0.92

IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol (2000) 0.91

Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection. Immunology (2001) 0.91

Activation of the first component of complement evidence for an internal activation step. J Immunol (1972) 0.91

Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen. Clin Exp Immunol (2002) 0.90

Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol (1996) 0.90

The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes. Prog Allergy (1982) 0.89

The role of the classical pathway for the bactericidal effect of normal sera against gram-negative bacteria. Curr Top Microbiol Immunol (1985) 0.89

Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. Clin Exp Immunol (1996) 0.89

Reversible inhibition of C1Q release from guinea pig macrophages by 2,2'-dipyridyl: Evidence for a posttranslational hydroxylation step in the biosynthesis of C1Q, a subcomponent of the first component of complement (C1). FEBS Lett (1978) 0.89

Ultracentrifugation studies on the native form of the first component of human complement (C1). FEBS Lett (1976) 0.89

Granulocyte elastase as a new biochemical marker in the diagnosis of chronic joint diseases. Rheumatol Int (1986) 0.88

The first component of complement in serum: evidence for a hitherto unrecognized factor in C1 necessary for internal activation. J Immunol (1973) 0.88

Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. J Immunol (1991) 0.88

The functions of endogenous C1q, a subcomponent of the first component of complement, as a receptor on the membrane of macrophages. Mol Immunol (1982) 0.88

Clinical and immunological studies in a case of selective complete C1q deficiency. Clin Exp Immunol (1979) 0.88

Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-gamma. FEBS Lett (2001) 0.87

Alpha-1 antitrypsin phenotypes in rheumatoid arthritis. Lancet (1977) 0.87

Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J Immunol (1996) 0.87

Expression analysis and functional activity of interleukin-7 splice variants. Genes Immun (2008) 0.86

Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor. Clin Diagn Lab Immunol (2002) 0.86

Differentiation of hemolytically active fluid-phase and cell-bound human C1q by an ant venom-derived polysaccharide. J Immunol (1980) 0.86

Contributions of C1q, bacterial lipopolysaccharide, and porins during attachment and ingestion phases of phagocytosis by murine macrophages. Infect Immun (1986) 0.86

Monoclonal TCR mRNA transcripts are preferentially detected in the TCR variable alpha chain in CD8(+) T-lymphocytes: implications for immunomonitoring. Int J Mol Med (1999) 0.86

Half-life of C1INH in hereditary angioneurotic oedema (HAE). Clin Allergy (1975) 0.85

Collagen-like complement component C1q is a membrane protein of human monocyte-derived macrophages that mediates endocytosis. J Immunol (1995) 0.85

Interleukin-7 (IL-7) and IL-7 splice variants affect differentiation of human neural progenitor cells. Genes Immun (2009) 0.85

The Cl inactivator from guinea pig serum. 3. Characterization and kinetic data of the reaction between the inactivator and EACl and EACl4. Immunochemistry (1972) 0.85

Purification and characterization of human, guinea pig and mouse C1q by fast protein liquid chromatography (FPLC). J Immunol Methods (1984) 0.84

Molecular cloning and characterization of the complementary DNA coding for the B-chain of murine Clq. FEBS Lett (1989) 0.84

CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol (1999) 0.84

Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures. Arthritis Rheum (1995) 0.84

MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 0.84

Mode of interaction of different polyanions with the first (C1,C1) the second (C2) and the fourth (C4) component of complement. IV. Activation of C1 in serum by polyanions. Immunology (1976) 0.83

C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J Biol Chem (1997) 0.83

Functional domains of the human C1q A-chain. Behring Inst Mitt (1993) 0.83

Immunofluorescence studies on the subcomponents of the first component of complement (C1): detection of C1q and C1s in different cells of biopsy material and on human as well as on guinea pig peritoneal macrophages. Immunobiology (1981) 0.83

Insoluble polyanions as activators of both pathways of complement. Immunology (1977) 0.83

Autoreactivity to mouse C1q in a murine model of SLE. Rheumatol Int (1995) 0.83

Modulation of mRNA expression and secretion of C1q in mouse macrophages by anti-inflammatory drugs and cAMP: evidence for the partial involvement of a pathway that includes cyclooxygenase, prostaglandin E2 and adenylate cyclase. Immunology (1995) 0.83

Non-sense and missense mutations in the structural genes of complement component C1q A and C chains are linked with two different types of complete selective C1q deficiencies. J Immunol (1995) 0.83